Amgen, CytomX Launch Up-to-$1.465B+ Cancer Immunotherapy Collaboration

Amgen will use CytomX’s Probody™ therapeutics platform to develop new cancer immunotherapies under a collaboration that could generate up to $1.465 billion-plus for CytomX.Amgen and CytomX have agreed to codevelop a CytomX Probody T-cell-engaging bispecific antibody construct against the epidermal growth factor receptor (EGFR), an oncology target expressed on multiple human cancer types.CytomX cited preclinical studies showing that its Probody versions of EGFRxCD3 bispecific therapeu